The efficacy of aripiprazole versus risperidone as augmentation therapy in the treatment of the resistant obsessive-compulsive disorder : a double-blind, randomized clinical trial
Source
Iranian Red Crescent Medical Journal
Issue
Vol. 20, Issue 7 (31 Jul. 2018), pp.1-7, 7 p.
Publisher
Publication Date
2018-07-31
Country of Publication
United Arab Emirates
No. of Pages
7
Main Subjects
Abstract EN
Background: Obsessive-compulsive disorder (OCD) is the fourth common psychiatric disorder.
Among the anxiety disorders, OCD has the least therapeutic response and 40-60% of OCD patients do not satisfactorily respond to the first-line standard treatment known as treatment-resistant OCD.
One of the best therapeutic strategies is the augmentation therapy, which is adding antipsychotics to the standard treatment (SSRIs).
Objectives: This study was aimed at comparing the efficacy of Risperidone and Aripiprazole as augmentation therapy in the resistant cases of obsessive-compulsive disorder.
Methods: In this double-blind randomized clinical trial, 100 patients with treatment-resistant OCD were diagnosed based on the DSM-IV-TR and were followed for 12-weeks.
The patients were randomly divided into two groups of Aripiprazole and Risperidone and received an average daily dose of 5 mg and 1.5 mg for twelve weeks, respectively.
The efficacy of treatment was measured and compared by the Yale-brown obsessive-compulsive scale (Y-BOCS) at 4, 8 and 12 weeks.
Results: The mean Y-BOCS score of patients in Risperidone and Aripiprazole groups were 25.26 ± 4.17 and 25.02 ± 4.46; respectively and had no significant difference (P = 0.79) at the beginning of the trial.
At the end of the study (12th week), it was changed for the Risperidone and Aripiprazole groups to 20.00±4.45 and 16.24±4.41, respectively (P < 0.001).
Furthermore, there was a significant decreasing trend of Y-BOCS scores in both groups, which was demonstrated by the repeated measurement analysis (P < 00.1).
Conclusions: It was found that both Aripiprazole and Risperidone could be effective in the treatment of treatment-resistant OCD patients.
However, Aripiprazole showed a higher efficacy compared to Risperidone.
American Psychological Association (APA)
Assarian, Fatimah& Ghurishi, Fatimah Sadat& Burna, Mahbubah& Razzaghuf, Muhammad Rida. 2018. The efficacy of aripiprazole versus risperidone as augmentation therapy in the treatment of the resistant obsessive-compulsive disorder : a double-blind, randomized clinical trial. Iranian Red Crescent Medical Journal،Vol. 20, no. 7, pp.1-7.
https://search.emarefa.net/detail/BIM-903561
Modern Language Association (MLA)
Assarian, Fatimah…[et al.]. The efficacy of aripiprazole versus risperidone as augmentation therapy in the treatment of the resistant obsessive-compulsive disorder : a double-blind, randomized clinical trial. Iranian Red Crescent Medical Journal Vol. 20, no. 7 (Jul. 2018), pp.1-7.
https://search.emarefa.net/detail/BIM-903561
American Medical Association (AMA)
Assarian, Fatimah& Ghurishi, Fatimah Sadat& Burna, Mahbubah& Razzaghuf, Muhammad Rida. The efficacy of aripiprazole versus risperidone as augmentation therapy in the treatment of the resistant obsessive-compulsive disorder : a double-blind, randomized clinical trial. Iranian Red Crescent Medical Journal. 2018. Vol. 20, no. 7, pp.1-7.
https://search.emarefa.net/detail/BIM-903561
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 6-7
Record ID
BIM-903561